GLP-1 agonists
Semaglutide, tirzepatide, and related incretin therapies.
Notify me when meaningful evidence changes.
0
Insufficient evidence · Stable
No history yet
⚠ Prescription or off-label use
Prescription medicine with significant gastrointestinal and metabolic effects. Use outside approved indications is not supported here.
Current assessment
Large cardiovascular outcome trials show reduced events in people with obesity or type 2 diabetes. Whether benefits extend to healthy ageing is unresolved.
- Regulatory status
- Approved for indication
- Availability
- Prescription only
- Category
- Prescription
- Human studies tracked
- 0
Evidence breakdown
Human evidence
0
Animal evidence
0
Mechanistic
0
Safety
50
What changed
Evidence events affecting this intervention
No published evidence events yet
Evidence timeline
Every recorded score change
No score history yet
Major human studies
No human studies tracked yet
Animal and mechanistic evidence
No preclinical studies tracked yet